REM (Risk Of Endometrial Malignancy)

NCT ID: NCT01830192

Last Updated: 2013-04-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

741 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to obtain a predictive model to asses the Risk of Endometrial Malignancy (REM) in women with ultrasound endometrial abnormalities.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective: It is often difficult to distinguish a benign endometrial disease from a malignancy and tools to help physician are needed, in order to triage patients into high and low risk of endometrial cancer (EC). The purpose of this study was to obtain a predictive model to asses the Risk of Endometrial Malignancy (REM) in women with ultrasound endometrial abnormalities.Women, between 45 and 80 years, diagnosed with ultrasound endometrial abnormalities and scheduled to have surgery were enrolled on a prospective study at Department of Gynaecologic Oncology of Campus Bio-Medico of Rome. Preoperative clinical, ultrasound and laboratory features were taken into account. Logistic regression algorithm was utilized to categorize patients into low and high risk groups for EC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometrial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Training set

We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative

Group Type OTHER

Training set

Intervention Type OTHER

We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative

VERIFICATION SET

We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative

Group Type OTHER

VERIFICATION SET

Intervention Type OTHER

We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Training set

We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative

Intervention Type OTHER

VERIFICATION SET

We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. aged between 45 and 80 years;
2. Eastern Cooperative Oncology Group performance status 0-2 according to World Health Organization (WHO) criteria;
3. informed consent obtained from the patients.

Exclusion Criteria

1. abnormal cardiac, haematological, renal, respiratory and/or hepatic functions;
2. presence of a previous malignancy;
3. presence of concomitant adnexal masses.
Minimum Eligible Age

45 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Campus Bio-Medico University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Roberto Angioli

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Roberto Angioli, MD

Role: PRINCIPAL_INVESTIGATOR

Campus Biomedico University of Rome

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

campus bio-medico of Rome

Rome, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

47/09 RA CBM

Identifier Type: -

Identifier Source: org_study_id

NCT01830179

Identifier Type: -

Identifier Source: nct_alias

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PET/MRI for Evaluation of Endometriosis
NCT06377553 ENROLLING_BY_INVITATION